T. Rowe Price Associates
BLCM

T. Rowe Price Associates’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

T. Rowe Price Associates’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,543
Closed -$1.31M – 2597
2017
Q4 		$1.31M Buy
15,543
+3
+0% +$294 ﹤0.01% 1691
2017
Q3 		$1.79M Buy
15,540
+1,221
+9% +$128K ﹤0.01% 1600
2017
Q2 		$1.67M Sell
14,319
-41,211
-74% -$5.12M ﹤0.01% 1599
2017
Q1 		$6.85M Sell
55,530
-42,924
-44% -$5.62M ﹤0.01% 1391
2016
Q4 		$13.4M Sell
98,454
-18,832
-16% -$3.34M ﹤0.01% 1250
2016
Q3 		$23.3M Buy
117,286
+4,652
+4% +$801K ﹤0.01% 1078
2016
Q2 		$14.6M Sell
112,634
-1,510
-1% -$168K ﹤0.01% 1200
2016
Q1 		$10.7M Sell
114,144
-3,205
-3% -$349K ﹤0.01% 1253
2015
Q4 		$23.8M Sell
117,349
-24,290
-17% -$4.35M 0.01% 1031
2015
Q3 		$20.6M Sell
141,639
-3,574
-2% -$656K ﹤0.01% 1076
2015
Q2 		$30.9M Sell
145,213
-7,610
-5% -$1.87M 0.01% 996
2015
Q1 		$34.5M Buy
152,823
+1,658
+1% +$401K 0.01% 965
2014
Q4 		$33.9M Buy
+151,165
New +$32.4M 0.01% 975

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates's BLCM Position: Q1 2018 in Review

T. Rowe Price Associates sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2018, closing a stake of 15,543 shares — an estimated $1.31M sold.

T. Rowe Price Associates first reported a position in BLCM in Q4 2014 and held it in 13 quarters. The position peaked at $34.5M in Q1 2015. 90 funds tracked by Wall St. Rank hold BLCM as of Q1 2018.

  • T. Rowe Price Associates reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • T. Rowe Price Associates sold 15,543 Bellicum Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.31M.
  • T. Rowe Price Associates first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 13 quarters.
  • T. Rowe Price Associates's Bellicum Pharmaceuticals, Inc. position peaked at $34.5M in Q1 2015.
  • 90 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2018.

Based on T. Rowe Price Associates's 13F filing for Q1 2018, filed 14 May 2018.